This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Macular Disorders  • Uveitis  • Drug Therapy  • Adverse Effects  • Drug Therapy, Other  • Immunology  • Immunology, Other  • Alert me on articles by topic  Social Bookmarking   What's this?

Weighing the Balance Between Local and Systemic Immunosuppression

Steven Yeh, MD; Robert B. Nussenblatt, MD, MPH

Arch Ophthalmol. 2008;126(9):1287-1289.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

The increasingly complex array of local and systemic immunosuppressive options available to ophthalmologists caring for patients with ocular inflammatory diseases requires thoughtful consideration of the risks and benefits associated with the introduction of each novel therapy. In this issue of the Archives, Callanan et al¹ report the long-term results of a large cohort of patients with uveitis treated with the fluocinolone acetonide (FA) intravitreal implant and present their appraisal of this medication. Their study contributes greatly to our understanding of the potential benefits of this local corticosteroid delivery system, and their discussion of reported complications is critical for patient counseling and risk assessment when considering the precise role of this therapy for patient care.

Jaffe et al² initially reported encouraging results on the efficacy of the FA implant for uveitis in a 34-week prospective, historically controlled, multicenter trial in 278 patients . . . [Full Text of this Article]

AUTHOR INFORMATION


CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?